About Fluoguide

A clinical-stage life science company

FluoGuide is a clinical-stage life science company developing targeted fluorescent imaging agents to improve precision in cancer surgery. The company’s lead product, FG001, is designed to help surgeons visualize cancer tissue in real time during operations, supporting more complete tumor removal while sparing healthy tissue.

FG001 targets uPAR (urokinase-type plasminogen activator receptor), a well-validated cancer-associated biomarker linked to tumor invasion and poor prognosis. The compound has demonstrated clear tumor-to-background contrast and a favorable safety profile in clinical studies.

FluoGuide’s technology integrates with existing surgical imaging systems and has potential across multiple solid cancer indications. The company has established collaborations with leading clinical centers and industry partners to support development and future commercialization.​

In 2025, FluoGuide strengthened its partner base through collaboration with Olympus and ZEISS Medical Technologies, alongside continued its collaborations with Intuitive Surgical and SurgVision (Bracco Group).​